A Phase 3 interventional study of Placebo and SAGE-547 60 μg/kg/h in Postpartum Depression, sponsored by Supernus Pharmaceuticals, Inc.. Completed at 32 sites in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-10-14.
Sponsored by Supernus Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 220 studies in Depression, Postpartum with a site in United States — 38 open to participants now, 49 under way, 3 of them phase 3. Depression, Postpartum · United States.
Among the 220 studies in Depression, Postpartum with a site in United States, this one is the 75th largest by enrollment of the 198 interventional ones that give a count, is one of 9 that started in 2016, is one of 12 in phase 3, and was the 79th registered.
569 studies on the registry are indexed under Depression, Postpartum; 134 are open to participants now.
Browse Depression, Postpartum studies →38 of the 220 studies in Depression, Postpartum with a site in United States are open now. Recruiting first, the newest first:
University of South Carolina · Sites in United States
Ages 18+ · Women only
University of Illinois at Chicago · Sites in United States
Ages 18+ · Women only
University of Florida · Sites in United States
Ages 15–49 · Women only
Lipocine Inc. · Sites in United States
Ages 15–45 · Women only
Northwestern University · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 87 Depression, Postpartum studies recruiting now, 54 (62%) set no upper age limit and 30 (34%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
220 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 20 · Phase 3 14 · Phase 4 7
First in 1996; this study’s year is marked. 9 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 138 is above the median of 104 across 454 interventional studies indexed under Depression, Postpartum.
Median enrollment 86 across the 198 interventional studies, 175 across the 22 observational. Of the 162 that completed or were terminated, 56 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 220 have an industry lead sponsor. The 10 most frequent:
Supernus Pharmaceuticals, Inc. is the lead sponsor of 64 studies on the registry; 6 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 26 (81%) have results posted.
Supernus Pharmaceuticals, Inc. has 8 studies filed under Depression, Postpartum — fewer than ten, so there is no comparison to draw.
22 of the studies in Depression, Postpartum with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05552053Phase 3Cedars-Sinai Medical CenterResources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women | 2026-12-31 |
| NCT07822321Phase 3Lipocine Inc.Brexanolone Lifting Outcomes Of Moms | 2027-08 |
| NCT05345834Children's National Research InstituteThe DC Mother-Infant Behavioral Wellness Program | 2026-11-30 |
| NCT06831968University of VirginiaClinical Validation of a Predictive Test for Postpartum Depression | 2026-11-30 |
| NCT06175104Children's Hospital Medical Center, CincinnatiHeartGPS: A Study Exploring the Effects of a Psychological Intervention for Parents and Their Babies After Prenatal Cardiac Diagnosis | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 220 studies in Depression, Postpartum with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to determine if SAGE-547 Injection infused intravenously at up to 90 micrograms per kilogram per hour (μg/kg/h) for 60 hours reduces depressive symptoms in participants with severe postpartum depression (PPD) compared to placebo injection as assessed by the change from baseline in Hamilton Rating Scale for Depression (HAM-D) total score.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined inclusion/exclusion criteria applied.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received infusion rates equivalent to either the 60 micrograms per kilogram per hour (μg/kg/h) or 90 μg/kg/h group.
Drug: Placebo
Participants received a 4-hour titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 56 hours), followed by a taper to 30 μg/kg/h (56 to 60 hours).
Drug: SAGE-547 60 μg/kg/h
Participants received a 4-hour dose titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 24 hours), then 90 μg/kg/h (24 to 52 hours), followed by a taper to 60 μg/kg/h (52 to 56 hours), and 30 μg/kg/h (56 to 60 hours).
Drug: SAGE-547 90 μg/kg/h
Intravenous infusion of matching placebo for either SAGE-547 60 μg/kg/h or 90 μg/kg/h.
Drug page: Brexanolone
Intravenous infusion of SAGE-547.
Drug page: Brexanolone
Intravenous infusion of SAGE-547.
Change From Baseline at 60 Hours in the 17-Item Hamilton Rating Scale for Depression (HAM-D) Total Score
The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.
Time frame: Baseline, Hour 60
Change From Baseline in HAM-D Total Score at Day 30
The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.
Time frame: Baseline, Day 30
Change From Baseline in HAM-D Total Score
The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.
Time frame: Baseline, Hours 2, 4, 8, 12, 24, 36, 48, 72, and Days 7, 14, and 21
Percentage of Participants With HAM-D Response
The HAM-D response is defined as having a 50% or greater reduction from baseline in HAM-D total score. The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.
Time frame: Hour 60, Days 7 and 30
Percentage of Participants With HAM-D Remission
The HAM-D remission is defined as having a HAM-D total score of ≤7. The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.
Time frame: Hour 60, Days 7 and 30
Change From Baseline in HAM-D Bech 6 Subscale
The HAM-D Bech 6 subscale score is calculated as the sum of the following six items: Item # 1 (depressed mood), Item # 2 (feelings of guilt), Item # 7 (work and activities), Item # 8 (retardation), Item # 10 (anxiety psychic), and Item # 13 (general somatic symptoms). Each item is scored in a range of 0 to 2 or 0 to 4, with higher scores indicating a greater degree of depression. The scores were transformed to a 100-point scale with a higher score indicating a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.
Time frame: Baseline, Hour 60, Days 7 and 30
Change From Baseline in HAM-D Individual Item Scores
The HAM-D comprises individual ratings of the following symptoms scored in a range of 0 to 2: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following symptoms are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.
Time frame: Baseline, Hour 2, Hour 4, Hour 8, Hour 12, Hour 24, Hour 36, Hour 48, Hour 60, Hour 72 and Days 7, 14, 21 and 30
Change From Baseline at Key Time Points in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in participants with mood disorders. It was designed as an adjunct to the HAM-D, to be more sensitive than the Hamilton Scale to the changes brought on by antidepressants and other forms of treatment. Each item yielded a score of 0 to 6. The MADRS total score was calculated as the sum of the 10 individual item scores, which ranged from 0 to 60. Higher MADRS scores indicates more severe depression. A negative change from baseline indicates less severe depression. A positive change from baseline indicates more severe depression.
Time frame: Baseline, Hour 60, Days 7 and 30
Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response
The CGI-I item employs a 7-point Likert scale to measure the overall improvement in the participant's condition post-treatment. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The CGI-I was only rated at post-treatment assessments. By definition, all CGI-I assessments were evaluated against baseline conditions. CGI-I response was defined as having a score of 1 (very much improved) or 2 (much improved).
Time frame: Hour 60, Days 7 and 30
Change From Baseline in the Generalized Anxiety Disorder 7-Item Scale (GAD-7) Total Score
The GAD-7 is a participant-rated, generalized anxiety symptom severity scale. Scoring for GAD-7 generalized anxiety is calculated by assigning scores of 0 = "not at all sure," 1 = "several days," 2 = "over half the days," and 3 = "nearly every day" to the response categories. The GAD-7 total score for the seven items ranges from 0 to 21, where a score of 0 to 4 = minimal anxiety, 5 to 9 = mild anxiety, 10 to 14 = moderate anxiety, and 15 to 21 = severe anxiety. The GAD-7 total score was calculated as the sum of the seven individual item scores. A negative change from baseline indicates less anxiety. A positive change from baseline indicates more anxiety.
Time frame: Baseline, Hour 60, Days 7, 14, 21 and 30
Percentage of Participants With Treatment-Emergent Adverse Events
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent AE (TEAE) is defined as an AE with onset on or after the start of study drug infusion, or any worsening of a pre-existing medical condition/AE with onset on or after the start of study drug infusion.
Time frame: Up to approximately 37 days.
Time to Change in Antidepressant Medication
The time to first start or increase in the dose and time to first stop or decrease in the dose of any antidepressant medication.
Time frame: Up to approximately 37 days.
Participants took part in the study at 32 centers in United States from 01 August 2016 to 19 October 2017.
| Milestone | Placebo | SAGE-547 60 μg/kg/h | SAGE-547 90 μg/kg/h |
|---|---|---|---|
| Started | 46 | 47 | 45 |
| Participants who received study drug | 43 | 38 | 41 |
| Completed | 42 | 35 | 36 |
| Not completed | 4 | 12 | 9 |
| Withdrew: Withdrawal by subject | 0 | 2 | 3 |
| Withdrew: Lost to follow-up | 1 | 1 | 2 |
| Withdrew: Randomized but not dosed | 3 | 9 | 4 |
The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.
| score on a scale | Placebo | SAGE-547 60 μg/kg/h | SAGE-547 90 μg/kg/h |
|---|---|---|---|
| Change From Baseline at 60 Hours in the 17-Item Hamilton Rating Scale for Depression (HAM-D) Total Score | -14.04 ± 1.148 | -19.54 ± 1.231 | -17.72 ± 1.193 |
The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.
| score on a scale | Placebo | SAGE-547 60 μg/kg/h | SAGE-547 90 μg/kg/h |
|---|---|---|---|
| Change From Baseline in HAM-D Total Score at Day 30 | -13.82 ± 1.324 | -19.45 ± 1.435 | -17.62 ± 1.400 |
The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.
| score on a scale | Placebo | SAGE-547 60 μg/kg/h | SAGE-547 90 μg/kg/h |
|---|---|---|---|
| Change at Hour 2 | -5.04 ± 0.669 | -4.99 ± 0.721 | -4.89 ± 0.707 |
| Change at Hour 4 | -6.88 ± 0.841 | -8.99 ± 0.902 | -7.18 ± 0.879 |
| Change at Hour 8 | -8.13 ± 0.928 | -10.18 ± 0.994 | -8.50 ± 0.966 |
| Change at Hour 12 | -9.79 ± 0.992 | -11.04 ± 1.069 | -9.07 ± 1.034 |
| Change at Hour 24 | -10.71 ± 1.121 | -15.00 ± 1.199 | -13.03 ± 1.157 |
| Change at Hour 36 | -12.58 ± 1.114 | -17.69 ± 1.203 | -13.93 ± 1.157 |
| Change at Hour 48 | -13.55 ± 1.195 | -18.04 ± 1.282 | -16.89 ± 1.239 |
| Change at Hour 72 | -14.67 ± 1.197 | -19.69 ± 1.285 | -17.19 ± 1.243 |
| Change at Day 7 | -13.34 ± 1.268 | -17.41 ± 1.353 | -14.93 ± 1.315 |
| Change at Day 14 | -14.64 ± 1.457 | -17.56 ± 1.586 | -15.64 ± 1.521 |
| Change at Day 21 | -13.23 ± 1.380 | -18.15 ± 1.529 | -16.74 ± 1.451 |
The HAM-D response is defined as having a 50% or greater reduction from baseline in HAM-D total score. The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.
| percentage of participants | Placebo | SAGE-547 60 μg/kg/h | SAGE-547 90 μg/kg/h |
|---|---|---|---|
| Hour 60 | 55.8 | 86.5 | 74.4 |
| Day 7 | 48.8 | 68.4 | 52.5 |
| Day 30 | 50.0 | 82.9 | 69.4 |
The HAM-D remission is defined as having a HAM-D total score of ≤7. The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.
| percentage of participants | Placebo | SAGE-547 60 μg/kg/h | SAGE-547 90 μg/kg/h |
|---|---|---|---|
| Hour 60 | 16.3 | 51.4 | 30.8 |
| Day 7 | 30.2 | 31.6 | 20.0 |
| Day 30 | 31.0 | 48.6 | 38.9 |
The HAM-D Bech 6 subscale score is calculated as the sum of the following six items: Item # 1 (depressed mood), Item # 2 (feelings of guilt), Item # 7 (work and activities), Item # 8 (retardation), Item # 10 (anxiety psychic), and Item # 13 (general somatic symptoms). Each item is scored in a range of 0 to 2 or 0 to 4, with higher scores indicating a greater degree of depression. The scores were transformed to a 100-point scale with a higher score indicating a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.
| score on a scale | Placebo | SAGE-547 60 μg/kg/h | SAGE-547 90 μg/kg/h |
|---|---|---|---|
| Hour 60 | -32.60 ± 2.962 | -44.67 ± 3.178 | -38.49 ± 3.081 |
| Day 7 | -29.43 ± 3.116 | -38.52 ± 3.327 | -31.67 ± 3.236 |
| Day 30 | -30.94 ± 3.122 | -42.62 ± 3.385 | -39.20 ± 3.304 |
The HAM-D comprises individual ratings of the following symptoms scored in a range of 0 to 2: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following symptoms are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.
| score on a scale | Placebo | SAGE-547 60 μg/kg/h | SAGE-547 90 μg/kg/h |
|---|---|---|---|
| Depressed Mood, Change at Hour 2 | -0.54 ± 0.133 | -0.54 ± 0.143 | -0.45 ± 0.139 |
| Depressed Mood, Change at Hour 4 | -0.79 ± 0.165 | -0.97 ± 0.176 | -0.79 ± 0.171 |
| Depressed Mood, Change at Hour 8 | -1.02 ± 0.166 | -1.23 ± 0.178 | -0.94 ± 0.172 |
| Depressed Mood, Change at Hour 12 | -1.33 ± 0.170 | -1.50 ± 0.184 | -1.15 ± 0.177 |
| Depressed Mood, Change at Hour 24 | -1.40 ± 0.163 | -1.40 ± 0.175 | -1.47 ± 0.169 |
| Depressed Mood, Change at Hour 36 | -1.47 ± 0.170 | -2.03 ± 0.184 | -1.49 ± 0.176 |
| Depressed Mood, Change at Hour 48 | -1.58 ± 0.173 | -2.07 ± 0.186 | -1.84 ± 0.180 |
| Depressed Mood, Change at Hour 60 | -1.56 ± 0.169 | -2.27 ± 0.181 | -1.92 ± 0.176 |
| Depressed Mood, Change at Hour 72 | -1.75 ± 0.162 | -2.32 ± 0.174 | -1.97 ± 0.169 |
| Depressed Mood, Change at Day 7 | -1.49 ± 0.170 | -1.94 ± 0.182 | -1.55 ± 0.177 |
| Depressed Mood, Change at Day 14 | -1.53 ± 0.205 | -2.06 ± 0.225 | -1.65 ± 0.213 |
| Depressed Mood, Change at Day 21 | -1.48 ± 0.204 | -1.79 ± 0.229 | -1.75 ± 0.214 |
| Depressed Mood, Change at Day 30 | -1.53 ± 0.170 | -2.19 ± 0.186 | -1.97 ± 0.183 |
| Feelings of Guilt, Change at Hour 2 | -0.46 ± 0.133 | -0.54 ± 0.143 | -0.40 ± 0.138 |
| Feelings of Guilt, Change at Hour 4 | -0.70 ± 0.157 | -1.12 ± 0.168 | -0.84 ± 0.162 |
| Feelings of Guilt, Change at Hour 8 | -0.84 ± 0.162 | -1.25 ± 0.173 | -0.94 ± 0.168 |
| Feelings of Guilt, Change at Hour 12 | -1.04 ± 0.164 | -1.25 ± 0.178 | -0.76 ± 0.171 |
| Feelings of Guilt, Change at Hour 24 | -1.04 ± 0.162 | -1.50 ± 0.173 | -1.03 ± 0.167 |
| Feelings of Guilt, Change at Hour 36 | -1.23 ± 0.150 | -1.59 ± 0.162 | -1.26 ± 0.156 |
| Feelings of Guilt, Change at Hour 48 | -1.25 ± 0.152 | -1.64 ± 0.163 | -1.60 ± 0.158 |
| Feelings of Guilt, Change at Hour 60 | -1.23 ± 0.149 | -1.68 ± 0.160 | -1.63 ± 0.155 |
| Feelings of Guilt, Change at Hour 72 | -1.42 ± 0.145 | -1.69 ± 0.157 | -1.57 ± 0.152 |
| Feelings of Guilt, Change at Day 7 | -1.18 ± 0.152 | -1.38 ± 0.163 | -1.36 ± 0.159 |
| Feelings of Guilt, Change at Day 14 | -1.33 ± 0.158 | -1.49 ± 0.173 | -1.56 ± 0.169 |
| Feelings of Guilt, Change at Day 21 | -1.10 ± 0.162 | -1.51 ± 0.181 | -1.51 ± 0.171 |
| Feelings of Guilt, Change at Day 30 | -1.40 ± 0.149 | -1.61 ± 0.163 | -1.62 ± 0.161 |
| Suicide, Change at Hour 2 | -0.57 ± 0.101 | -0.87 ± 0.107 | -0.48 ± 0.104 |
| Suicide, Change at Hour 4 | -0.64 ± 0.098 | -0.92 ± 0.105 | -0.61 ± 0.101 |
| Suicide, Change at Hour 8 | -0.81 ± 0.088 | -1.00 ± 0.094 | -0.63 ± 0.091 |
| Suicide, Change at Hour 12 | -0.92 ± 0.089 | -0.89 ± 0.096 | -0.66 ± 0.092 |
| Suicide, Change at Hour 24 | -0.87 ± 0.086 | -0.96 ± 0.092 | -0.68 ± 0.088 |
| Suicide, Change at Hour 36 | -0.90 ± 0.068 | -1.00 ± 0.074 | -0.75 ± 0.071 |
| Suicide, Change at Hour 48 | -0.88 ± 0.063 | -0.94 ± 0.069 | -0.95 ± 0.066 |
| Suicide, Change at Hour 60 | -0.81 ± 0.065 | -1.03 ± 0.071 | -0.98 ± 0.069 |
| Suicide, Change at Hour 72 | -0.88 ± 0.068 | -1.01 ± 0.074 | -0.90 ± 0.071 |
| Suicide, Change at Day 7 | -0.71 ± 0.089 | -0.90 ± 0.095 | -0.77 ± 0.093 |
| Suicide, Change at Day 14 | -0.92 ± 0.084 | -0.99 ± 0.093 | -0.80 ± 0.090 |
| Suicide, Change at Day 21 | -0.61 ± 0.133 | -0.80 ± 0.152 | -0.88 ± 0.141 |
| Suicide, Change at Day 30 | -0.76 ± 0.080 | -0.99 ± 0.088 | -0.88 ± 0.086 |
| Insomnia - Early, Change at Hour 2 | -0.27 ± 0.078 | -0.04 ± 0.084 | -0.19 ± 0.082 |
| Insomnia - Early, Change at Hour 4 | -0.29 ± 0.097 | -0.22 ± 0.104 | -0.29 ± 0.100 |
| Insomnia - Early, Change at Hour 8 | -0.29 ± 0.103 | -0.17 ± 0.110 | -0.36 ± 0.107 |
| Insomnia - Early, Change at Hour 12 | -0.22 ± 0.092 | -0.25 ± 0.100 | -0.26 ± 0.097 |
| Insomnia - Early, Change at Hour 24 | -0.47 ± 0.138 | -1.10 ± 0.149 | -0.87 ± 0.142 |
| Insomnia - Early, Change at Hour 36 | -0.55 ± 0.142 | -1.16 ± 0.155 | -0.84 ± 0.147 |
| Insomnia - Early, Change at Hour 48 | -0.76 ± 0.144 | -1.07 ± 0.155 | -1.27 ± 0.149 |
| Insomnia - Early, Change at Hour 60 | -0.85 ± 0.140 | -1.10 ± 0.151 | -1.19 ± 0.146 |
| Insomnia - Early, Change at Hour 72 | -0.57 ± 0.142 | -0.96 ± 0.153 | -0.91 ± 0.148 |
| Insomnia - Early, Change at Day 7 | -0.69 ± 0.144 | -1.20 ± 0.154 | -0.97 ± 0.150 |
| Insomnia - Early, Change at Day 14 | -0.97 ± 0.174 | -1.19 ± 0.192 | -1.06 ± 0.182 |
| Insomnia - Early, Change at Day 21 | -0.69 ± 0.154 | -1.28 ± 0.173 | -1.11 ± 0.160 |
| Insomnia - Early, Change at Day 30 | -0.67 ± 0.141 | -1.34 ± 0.155 | -1.09 ± 0.153 |
| Insomnia - Middle, Change at Hour 2 | -0.13 ± 0.073 | 0.03 ± 0.078 | -0.17 ± 0.076 |
| Insomnia - Middle, Change at Hour 4 | -0.16 ± 0.096 | -0.21 ± 0.102 | -0.24 ± 0.099 |
| Insomnia - Middle, Change at Hour 8 | -0.20 ± 0.099 | -0.16 ± 0.105 | -0.32 ± 0.102 |
| Insomnia - Middle, Change at Hour 12 | -0.16 ± 0.091 | -0.18 ± 0.098 | -0.22 ± 0.095 |
| Insomnia - Middle, Change at Hour 24 | -0.57 ± 0.135 | -0.98 ± 0.145 | -0.93 ± 0.139 |
| Insomnia - Middle, Change at Hour 36 | -0.74 ± 0.130 | -1.03 ± 0.141 | -1.02 ± 0.135 |
| Insomnia - Middle, Change at Hour 48 | -0.90 ± 0.132 | -1.17 ± 0.142 | -1.19 ± 0.137 |
| Insomnia - Middle, Change at Hour 60 | -0.83 ± 0.130 | -1.22 ± 0.140 | -1.23 ± 0.135 |
| Insomnia - Middle, Change at Hour 72 | -0.93 ± 0.132 | -1.22 ± 0.143 | -1.09 ± 0.138 |
| Insomnia - Middle, Change at Day 7 | -0.95 ± 0.128 | -1.05 ± 0.136 | -0.87 ± 0.133 |
| Insomnia - Middle, Change at Day 14 | -0.72 ± 0.146 | -1.36 ± 0.161 | -0.98 ± 0.154 |
| Insomnia - Middle, Change at Day 21 | -0.77 ± 0.146 | -1.27 ± 0.164 | -0.90 ± 0.152 |
| Insomnia - Middle, Change at Day 30 | -0.78 ± 0.134 | -1.21 ± 0.147 | -0.99 ± 0.144 |
| Insomnia - Late, Change at Hour 2 | -0.16 ± 0.090 | 0.01 ± 0.096 | -0.22 ± 0.094 |
| Insomnia - Late, Change at Hour 4 | -0.16 ± 0.104 | -0.12 ± 0.111 | -0.34 ± 0.108 |
| Insomnia - Late, Change at Hour 8 | -0.14 ± 0.103 | -0.20 ± 0.110 | -0.37 ± 0.106 |
| Insomnia - Late, Change at Hour 12 | -0.16 ± 0.103 | -0.01 ± 0.111 | -0.31 ± 0.107 |
| Insomnia - Late, Change at Hour 24 | -0.68 ± 0.123 | -0.94 ± 0.133 | -0.95 ± 0.127 |
| Insomnia - Late, Change at Hour 36 | -0.75 ± 0.127 | -0.91 ± 0.139 | -0.90 ± 0.132 |
| Insomnia - Late, Change at Hour 48 | -0.89 ± 0.125 | -1.16 ± 0.135 | -1.15 ± 0.130 |
| Insomnia - Late, Change at Hour 60 | -0.89 ± 0.121 | -1.16 ± 0.130 | -1.22 ± 0.126 |
| Insomnia - Late, Change at Hour 72 | -1.07 ± 0.121 | -1.13 ± 0.131 | -1.12 ± 0.126 |
| Insomnia - Late, Change at Day 7 | -0.89 ± 0.126 | -0.80 ± 0.135 | -1.04 ± 0.132 |
| Insomnia - Late, Change at Day 14 | -0.79 ± 0.155 | -0.96 ± 0.172 | -0.86 ± 0.164 |
| Insomnia - Late, Change at Day 21 | -0.77 ± 0.157 | -0.89 ± 0.176 | -0.74 ± 0.164 |
| Insomnia - Late, Change at Day 30 | -0.77 ± 0.130 | -1.03 ± 0.143 | -1.09 ± 0.140 |
| Work and Activities, Change at Hour 2 | -0.30 ± 0.105 | -0.43 ± 0.113 | -0.25 ± 0.111 |
| Work and Activities, Change at Hour 4 | -0.51 ± 0.126 | -0.74 ± 0.135 | -0.43 ± 0.131 |
| Work and Activities, Change at Hour 8 | -0.81 ± 0.160 | -0.95 ± 0.170 | -0.67 ± 0.165 |
| Work and Activities, Change at Hour 12 | -1.02 ± 0.160 | -1.20 ± 0.173 | -0.83 ± 0.166 |
| Work and Activities, Change at Hour 24 | -1.07 ± 0.169 | -1.19 ± 0.180 | -1.04 ± 0.174 |
| Work and Activities, Change at Hour 36 | -1.39 ± 0.162 | -1.77 ± 0.176 | -1.09 ± 0.168 |
| Work and Activities, Change at Hour 48 | -1.51 ± 0.179 | -1.80 ± 0.192 | -1.57 ± 0.185 |
| Work and Activities, Change at Hour 60 | -1.46 ± 0.171 | -2.04 ± 0.184 | -1.70 ± 0.178 |
| Work and Activities, Change at Hour 72 | -1.67 ± 0.164 | -2.18 ± 0.177 | -1.67 ± 0.171 |
| Work and Activities, Change at Day 7 | -1.39 ± 0.176 | -1.82 ± 0.187 | -1.57 ± 0.182 |
| Work and Activities, Change at Day 14 | -1.58 ± 0.198 | -1.57 ± 0.218 | -1.60 ± 0.208 |
| Work and Activities, Change at Day 21 | -1.35 ± 0.191 | -1.96 ± 0.214 | -1.87 ± 0.200 |
| Work and Activities, Change at Day 30 | -1.55 ± 0.174 | -2.08 ± 0.189 | -1.93 ± 0.185 |
| Retardation, Change at Hour 2 | -0.18 ± 0.084 | 0.17 ± 0.090 | -0.01 ± 0.087 |
| Retardation, Change at Hour 4 | -0.34 ± 0.090 | -0.02 ± 0.096 | -0.03 ± 0.093 |
| Retardation, Change at Hour 8 | -0.36 ± 0.092 | -0.20 ± 0.098 | -0.16 ± 0.095 |
| Retardation, Change at Hour 12 | -0.57 ± 0.099 | -0.47 ± 0.107 | -0.42 ± 0.103 |
| Retardation, Change at Hour 24 | -0.48 ± 0.092 | -0.47 ± 0.099 | -0.47 ± 0.095 |
| Retardation, Change at Hour 36 | -0.71 ± 0.103 | -0.87 ± 0.112 | -0.65 ± 0.107 |
| Retardation, Change at Hour 48 | -0.57 ± 0.098 | -0.70 ± 0.105 | -0.60 ± 0.101 |
| Retardation, Change at Hour 60 | -0.76 ± 0.090 | -0.84 ± 0.097 | -0.74 ± 0.094 |
| Retardation, Change at Hour 72 | -0.67 ± 0.092 | -0.87 ± 0.099 | -0.80 ± 0.096 |
| Retardation, Change at Day 7 | -0.67 ± 0.091 | -1.02 ± 0.097 | -0.70 ± 0.095 |
| Retardation, Change at Day 14 | -0.74 ± 0.117 | -0.87 ± 0.128 | -0.77 ± 0.123 |
| Retardation, Change at Day 21 | -0.72 ± 0.104 | -1.05 ± 0.115 | -0.81 ± 0.108 |
| Retardation, Change at Day 30 | -0.66 ± 0.088 | -1.08 ± 0.096 | -0.91 ± 0.095 |
| Agitation, Change at Hour 2 | -0.46 ± 0.108 | -0.52 ± 0.115 | -0.45 ± 0.111 |
| Agitation, Change at Hour 4 | -0.56 ± 0.103 | -0.70 ± 0.109 | -0.52 ± 0.106 |
| Agitation, Change at Hour 8 | -0.51 ± 0.112 | -0.68 ± 0.119 | -0.55 ± 0.116 |
| Agitation, Change at Hour 12 | -0.56 ± 0.114 | -0.65 ± 0.123 | -0.59 ± 0.118 |
| Agitation, Change at Hour 24 | -0.54 ± 0.108 | -0.86 ± 0.115 | -0.69 ± 0.110 |
| Agitation, Change at Hour 36 | -0.63 ± 0.111 | -0.82 ± 0.121 | -0.74 ± 0.115 |
| Agitation, Change at Hour 48 | -0.74 ± 0.098 | -0.78 ± 0.105 | -0.78 ± 0.102 |
| Agitation, Change at Hour 60 | -0.58 ± 0.105 | -0.85 ± 0.113 | -0.70 ± 0.110 |
| Agitation, Change at Hour 72 | -0.65 ± 0.112 | -0.85 ± 0.120 | -0.82 ± 0.116 |
| Agitation, Change at Day 7 | -0.60 ± 0.098 | -0.78 ± 0.104 | -0.66 ± 0.102 |
| Agitation, Change at Day 14 | -0.87 ± 0.114 | -0.75 ± 0.126 | -0.82 ± 0.121 |
| Agitation, Change at Day 21 | -0.61 ± 0.142 | -0.69 ± 0.161 | -0.76 ± 0.149 |
| Agitation, Change at Day 30 | -0.64 ± 0.112 | -0.80 ± 0.122 | -0.62 ± 0.121 |
| Anxiety Psychic, Change at Hour 2 | -0.60 ± 0.134 | -0.70 ± 0.144 | -0.76 ± 0.140 |
| Anxiety Psychic, Change at Hour 4 | -0.90 ± 0.158 | -1.26 ± 0.169 | -1.12 ± 0.164 |
| Anxiety Psychic, Change at Hour 8 | -1.25 ± 0.161 | -1.41 ± 0.172 | -1.22 ± 0.167 |
| Anxiety Psychic, Change at Hour 12 | -1.39 ± 0.154 | -1.52 ± 0.167 | -1.35 ± 0.161 |
| Anxiety Psychic, Change at Hour 24 | -1.16 ± 0.148 | -1.79 ± 0.159 | -1.59 ± 0.153 |
| Anxiety Psychic, Change at Hour 36 | -1.37 ± 0.149 | -1.99 ± 0.162 | -1.41 ± 0.155 |
| Anxiety Psychic, Change at Hour 48 | -1.41 ± 0.149 | -1.86 ± 0.161 | -1.71 ± 0.156 |
| Anxiety Psychic, Change at Hour 60 | -1.48 ± 0.141 | -1.97 ± 0.152 | -1.64 ± 0.149 |
| Anxiety Psychic, Change at Hour 72 | -1.55 ± 0.152 | -1.84 ± 0.164 | -1.61 ± 0.159 |
| Anxiety Psychic, Change at Day 7 | -1.25 ± 0.149 | -1.44 ± 0.160 | -1.30 ± 0.156 |
| Anxiety Psychic, Change at Day 14 | -1.42 ± 0.184 | -1.45 ± 0.204 | -1.17 ± 0.195 |
| Anxiety Psychic, Change at Day 21 | -1.17 ± 0.197 | -1.26 ± 0.221 | -1.34 ± 0.207 |
| Anxiety Psychic, Change at Day 30 | -1.15 ± 0.161 | -1.45 ± 0.176 | -1.43 ± 0.173 |
| Anxiety Somatic, Change at Hour 2 | -0.56 ± 0.133 | -0.67 ± 0.142 | -0.75 ± 0.137 |
| Anxiety Somatic, Change at Hour 4 | -0.86 ± 0.144 | -1.09 ± 0.154 | -0.88 ± 0.149 |
| Anxiety Somatic, Change at Hour 8 | -0.79 ± 0.135 | -1.22 ± 0.145 | -1.05 ± 0.140 |
| Anxiety Somatic, Change at Hour 12 | -0.86 ± 0.130 | -1.16 ± 0.141 | -0.91 ± 0.135 |
| Anxiety Somatic, Change at Hour 24 | -0.77 ± 0.116 | -1.24 ± 0.125 | -1.12 ± 0.120 |
| Anxiety Somatic, Change at Hour 36 | -0.86 ± 0.127 | -1.34 ± 0.140 | -1.08 ± 0.133 |
| Anxiety Somatic, Change at Hour 48 | -0.86 ± 0.125 | -1.42 ± 0.136 | -1.20 ± 0.131 |
| Anxiety Somatic, Change at Hour 60 | -1.00 ± 0.122 | -1.58 ± 0.132 | -1.31 ± 0.128 |
| Anxiety Somatic, Change at Hour 72 | -0.91 ± 0.131 | -1.58 ± 0.142 | -1.29 ± 0.137 |
| Anxiety Somatic, Change at Day 7 | -0.91 ± 0.134 | -1.28 ± 0.143 | -0.98 ± 0.140 |
| Anxiety Somatic, Change at Day 14 | -0.70 ± 0.153 | -1.08 ± 0.169 | -0.88 ± 0.162 |
| Anxiety Somatic, Change at Day 21 | -0.94 ± 0.155 | -1.40 ± 0.175 | -1.05 ± 0.163 |
| Anxiety Somatic, Change at Day 30 | -0.80 ± 0.151 | -1.40 ± 0.166 | -0.99 ± 0.163 |
| Somatic Symptoms GI, Change at Hour 2 | -0.28 ± 0.110 | -0.29 ± 0.118 | -0.30 ± 0.114 |
| Somatic Symptoms GI, Change at Hour 4 | -0.28 ± 0.103 | -0.55 ± 0.111 | -0.44 ± 0.107 |
| Somatic Symptoms GI, Change at Hour 8 | -0.42 ± 0.109 | -0.60 ± 0.117 | -0.57 ± 0.113 |
| Somatic Symptoms GI, Change at Hour 12 | -0.51 ± 0.111 | -0.79 ± 0.121 | -0.56 ± 0.116 |
| Somatic Symptoms GI, Change at Hour 24 | -0.47 ± 0.115 | -0.88 ± 0.123 | -0.79 ± 0.118 |
| Somatic Symptoms GI, Change at Hour 36 | -0.54 ± 0.111 | -1.14 ± 0.122 | -0.78 ± 0.116 |
| Somatic Symptoms GI, Change at Hour 48 | -0.61 ± 0.110 | -1.16 ± 0.119 | -0.84 ± 0.115 |
| Somatic Symptoms GI, Change at Hour 60 | -0.82 ± 0.100 | -1.24 ± 0.109 | -0.96 ± 0.106 |
| Somatic Symptoms GI, Change at Hour 72 | -0.68 ± 0.102 | -1.23 ± 0.111 | -1.01 ± 0.107 |
| Somatic Symptoms GI, Change at Day 7 | -0.63 ± 0.114 | -1.00 ± 0.123 | -0.66 ± 0.119 |
| Somatic Symptoms GI, Change at Day 14 | -0.77 ± 0.126 | -1.03 ± 0.139 | -0.89 ± 0.134 |
| Somatic Symptoms GI, Change at Day 21 | -0.70 ± 0.132 | -1.17 ± 0.149 | -0.91 ± 0.139 |
| Somatic Symptoms GI, Change at Day 30 | -0.82 ± 0.112 | -1.14 ± 0.123 | -0.91 ± 0.121 |
| Somatic Symptoms General, Change at Hour 2 | -0.23 ± 0.086 | -0.28 ± 0.092 | -0.14 ± 0.089 |
| Somatic Symptoms General, Change at Hour 4 | -0.27 ± 0.093 | -0.44 ± 0.099 | -0.33 ± 0.096 |
| Somatic Symptoms General, Change at Hour 8 | -0.27 ± 0.093 | -0.33 ± 0.099 | -0.28 ± 0.096 |
| Somatic Symptoms General, Change at Hour 12 | -0.51 ± 0.108 | -0.50 ± 0.117 | -0.49 ± 0.113 |
| Somatic Symptoms General, Change at Hour 24 | -0.60 ± 0.119 | -0.67 ± 0.127 | -0.55 ± 0.122 |
| Somatic Symptoms General, Change at Hour 36 | -0.64 ± 0.111 | -0.70 ± 0.122 | -0.79 ± 0.116 |
| Somatic Symptoms General, Change at Hour 48 | -0.67 ± 0.113 | -1.05 ± 0.122 | -0.90 ± 0.117 |
| Somatic Symptoms General, Change at Hour 60 | -0.78 ± 0.111 | -1.06 ± 0.120 | -0.95 ± 0.117 |
| Somatic Symptoms General, Change at Hour 72 | -0.81 ± 0.113 | -1.26 ± 0.121 | -1.00 ± 0.117 |
| Somatic Symptoms General, Change at Day 7 | -0.62 ± 0.121 | -0.91 ± 0.129 | -0.61 ± 0.125 |
| Somatic Symptoms General, Change at Day 14 | -0.64 ± 0.138 | -0.92 ± 0.152 | -0.59 ± 0.144 |
| Somatic Symptoms General, Change at Day 21 | -0.55 ± 0.138 | -1.04 ± 0.154 | -0.72 ± 0.144 |
| Somatic Symptoms General, Change at Day 30 | -0.66 ± 0.129 | -1.00 ± 0.140 | -0.95 ± 0.137 |
| Genital Symptoms, Change at Hour 2 | 0.00 ± 0.055 | 0.00 ± 0.059 | -0.16 ± 0.057 |
| Genital Symptoms, Change at Hour 4 | 0.00 ± 0.067 | -0.11 ± 0.072 | -0.13 ± 0.069 |
| Genital Symptoms, Change at Hour 8 | -0.07 ± 0.087 | -0.16 ± 0.093 | -0.16 ± 0.090 |
| Genital Symptoms, Change at Hour 12 | -0.07 ± 0.075 | -0.08 ± 0.082 | -0.24 ± 0.079 |
| Genital Symptoms, Change at Hour 24 | -0.16 ± 0.100 | -0.28 ± 0.106 | -0.28 ± 0.102 |
| Genital Symptoms, Change at Hour 36 | -0.23 ± 0.102 | -0.46 ± 0.111 | -0.51 ± 0.106 |
| Genital Symptoms, Change at Hour 48 | -0.35 ± 0.107 | -0.46 ± 0.115 | -0.63 ± 0.110 |
| Genital Symptoms, Change at Hour 60 | -0.35 ± 0.108 | -0.48 ± 0.116 | -0.67 ± 0.112 |
| Genital Symptoms, Change at Hour 72 | -0.32 ± 0.107 | -0.57 ± 0.115 | -0.72 ± 0.110 |
| Genital Symptoms, Change at Day 7 | -0.51 ± 0.113 | -0.71 ± 0.120 | -0.79 ± 0.117 |
| Genital Symptoms, Change at Day 14 | -0.49 ± 0.131 | -0.70 ± 0.144 | -0.83 ± 0.138 |
| Genital Symptoms, Change at Day 21 | -0.68 ± 0.141 | -0.90 ± 0.159 | -0.87 ± 0.147 |
| Genital Symptoms, Change at Day 30 | -0.82 ± 0.131 | -0.97 ± 0.143 | -0.95 ± 0.140 |
| Hypochondriasis, Change at Hour 2 | -0.23 ± 0.105 | -0.29 ± 0.113 | -0.34 ± 0.109 |
| Hypochondriasis, Change at Hour 4 | -0.32 ± 0.111 | -0.39 ± 0.119 | -0.34 ± 0.116 |
| Hypochondriasis, Change at Hour 8 | -0.23 ± 0.114 | -0.47 ± 0.122 | -0.41 ± 0.118 |
| Hypochondriasis, Change at Hour 12 | -0.32 ± 0.109 | -0.41 ± 0.118 | -0.44 ± 0.114 |
| Hypochondriasis, Change at Hour 24 | -0.39 ± 0.105 | -0.55 ± 0.112 | -0.48 ± 0.109 |
| Hypochondriasis, Change at Hour 36 | -0.39 ± 0.104 | -0.61 ± 0.113 | -0.49 ± 0.109 |
| Hypochondriasis, Change at Hour 48 | -0.49 ± 0.105 | -0.63 ± 0.113 | -0.58 ± 0.109 |
| Hypochondriasis, Change at Hour 60 | -0.49 ± 0.100 | -0.60 ± 0.108 | -0.59 ± 0.105 |
| Hypochondriasis, Change at Hour 72 | -0.60 ± 0.098 | -0.66 ± 0.106 | -0.55 ± 0.103 |
| Hypochondriasis, Change at Day 7 | -0.49 ± 0.095 | -0.68 ± 0.102 | -0.58 ± 0.100 |
| Hypochondriasis, Change at Day 14 | -0.54 ± 0.120 | -0.59 ± 0.132 | -0.51 ± 0.127 |
| Hypochondriasis, Change at Day 21 | -0.84 ± 0.107 | -0.80 ± 0.119 | -0.57 ± 0.114 |
| Hypochondriasis, Change at Day 30 | -0.60 ± 0.099 | -0.66 ± 0.109 | -0.60 ± 0.108 |
| Loss of Weight, Change at Hour 2 | -0.05 ± 0.057 | 0.03 ± 0.061 | 0.06 ± 0.059 |
| Loss of Weight, Change at Hour 4 | -0.07 ± 0.052 | -0.04 ± 0.055 | 0.01 ± 0.054 |
| Loss of Weight, Change at Hour 8 | -0.07 ± 0.060 | -0.02 ± 0.064 | -0.04 ± 0.062 |
| Loss of Weight, Change at Hour 12 | -0.09 ± 0.068 | 0.03 ± 0.074 | -0.09 ± 0.071 |
| Loss of Weight, Change at Hour 24 | -0.07 ± 0.084 | -0.12 ± 0.090 | -0.24 ± 0.086 |
| Loss of Weight, Change at Hour 36 | -0.14 ± 0.076 | -0.10 ± 0.082 | -0.19 ± 0.079 |
| Loss of Weight, Change at Hour 48 | -0.05 ± 0.083 | -0.12 ± 0.089 | -0.26 ± 0.086 |
| Loss of Weight, Change at Hour 60 | -0.09 ± 0.095 | -0.26 ± 0.102 | -0.35 ± 0.098 |
| Loss of Weight, Change at Hour 72 | -0.14 ± 0.090 | -0.20 ± 0.097 | -0.26 ± 0.094 |
| Loss of Weight, Change at Day 7 | -0.30 ± 0.129 | -0.36 ± 0.137 | -0.60 ± 0.135 |
| Loss of Weight, Change at Day 14 | -0.43 ± 0.150 | -0.42 ± 0.164 | -0.64 ± 0.158 |
| Loss of Weight, Change at Day 21 | -0.49 ± 0.160 | -0.59 ± 0.177 | -0.61 ± 0.169 |
| Loss of Weight, Change at Day 30 | -0.24 ± 0.133 | -0.55 ± 0.144 | -0.48 ± 0.143 |
| Insight, Change at Hour 2 | -0.01 ± 0.037 | 0.02 ± 0.040 | 0.02 ± 0.039 |
| Insight, Change at Hour 4 | -0.01 ± 0.037 | -0.01 ± 0.040 | 0.04 ± 0.039 |
| Insight, Change at Hour 8 | -0.03 ± 0.037 | -0.04 ± 0.040 | 0.04 ± 0.039 |
| Insight, Change at Hour 12 | -0.03 ± 0.037 | -0.06 ± 0.041 | 0.07 ± 0.039 |
| Insight, Change at Hour 24 | 0.04 ± 0.038 | -0.01 ± 0.040 | 0.04 ± 0.039 |
| Insight, Change at Hour 36 | -0.03 ± 0.037 | -0.04 ± 0.041 | -0.01 ± 0.039 |
| Insight, Change at Hour 48 | -0.03 ± 0.037 | 0.02 ± 0.040 | 0.02 ± 0.039 |
| Insight, Change at Hour 60 | -0.06 ± 0.037 | -0.06 ± 0.040 | -0.09 ± 0.039 |
| Insight, Change at Hour 72 | -0.06 ± 0.037 | -0.01 ± 0.040 | -0.06 ± 0.039 |
| Insight, Change at Day 7 | -0.06 ± 0.037 | -0.06 ± 0.040 | -0.03 ± 0.039 |
| Insight, Change at Day 14 | -0.03 ± 0.041 | -0.07 ± 0.045 | -0.09 ± 0.044 |
| Insight, Change at Day 21 | -0.10 ± 0.042 | -0.08 ± 0.047 | -0.09 ± 0.044 |
| Insight, Change at Day 30 | -0.01 ± 0.038 | -0.06 ± 0.041 | -0.08 ± 0.041 |
The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in participants with mood disorders. It was designed as an adjunct to the HAM-D, to be more sensitive than the Hamilton Scale to the changes brought on by antidepressants and other forms of treatment. Each item yielded a score of 0 to 6. The MADRS total score was calculated as the sum of the 10 individual item scores, which ranged from 0 to 60. Higher MADRS scores indicates more severe depression. A negative change from baseline indicates less severe depression. A positive change from baseline indicates more severe depression.
| score on a scale | Placebo | SAGE-547 60 μg/kg/h | SAGE-547 90 μg/kg/h |
|---|---|---|---|
| Hour 60 | -19.98 ± 1.688 | -26.84 ± 1.822 | -24.19 ± 1.797 |
| Day 7 | -19.01 ± 1.865 | -23.31 ± 2.001 | -20.32 ± 1.982 |
| Day 30 | -19.43 ± 1.917 | -25.06 ± 2.091 | -23.02 ± 2.080 |
The CGI-I item employs a 7-point Likert scale to measure the overall improvement in the participant's condition post-treatment. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The CGI-I was only rated at post-treatment assessments. By definition, all CGI-I assessments were evaluated against baseline conditions. CGI-I response was defined as having a score of 1 (very much improved) or 2 (much improved).
| percentage of participants | Placebo | SAGE-547 60 μg/kg/h | SAGE-547 90 μg/kg/h |
|---|---|---|---|
| Hour 60 | 55.8 | 83.8 | 82.1 |
| Day 7 | 46.5 | 71.1 | 64.1 |
| Day 30 | 52.4 | 80.0 | 72.2 |
The GAD-7 is a participant-rated, generalized anxiety symptom severity scale. Scoring for GAD-7 generalized anxiety is calculated by assigning scores of 0 = "not at all sure," 1 = "several days," 2 = "over half the days," and 3 = "nearly every day" to the response categories. The GAD-7 total score for the seven items ranges from 0 to 21, where a score of 0 to 4 = minimal anxiety, 5 to 9 = mild anxiety, 10 to 14 = moderate anxiety, and 15 to 21 = severe anxiety. The GAD-7 total score was calculated as the sum of the seven individual item scores. A negative change from baseline indicates less anxiety. A positive change from baseline indicates more anxiety.
| score on a scale | Placebo | SAGE-547 60 μg/kg/h | SAGE-547 90 μg/kg/h |
|---|---|---|---|
| Hour 60 | -6.95 ± 1.012 | -8.08 ± 1.095 | -7.99 ± 1.087 |
| Day 7 | -6.57 ± 0.947 | -9.13 ± 1.025 | -6.32 ± 1.034 |
| Day 14 | -8.60 ± 1.081 | -9.20 ± 1.210 | -8.71 ± 1.191 |
| Day 21 | -8.47 ± 1.093 | -8.53 ± 1.224 | -9.22 ± 1.199 |
| Day 30 | -7.70 ± 1.023 | -9.72 ± 1.129 | -9.15 ± 1.135 |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent AE (TEAE) is defined as an AE with onset on or after the start of study drug infusion, or any worsening of a pre-existing medical condition/AE with onset on or after the start of study drug infusion.
| percentage of participants | Placebo | SAGE-547 60 μg/kg/h | SAGE-547 90 μg/kg/h |
|---|---|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events | 51.2 | 50.0 | 53.7 |
The time to first start or increase in the dose and time to first stop or decrease in the dose of any antidepressant medication.
| days | Placebo | SAGE-547 60 μg/kg/h | SAGE-547 90 μg/kg/h |
|---|---|---|---|
| Time to first start/increase in dose | 16 (5 to 22) | 12 (5 to 34) | 8 (4 to 29) |
| Time to first stop/decrease in dose | — | 29 (29 to 29) | 19 (19 to 19) |
Collected over Up to approximately 37 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/43 (0%) | 0/43 (0%) | 9/43 (20.9%) |
| SAGE-547 60 μg/kg/h | 0/38 (0%) | 1/38 (2.6%) | 17/38 (44.7%) |
| SAGE-547 90 μg/kg/h | 0/41 (0%) | 0/41 (0%) | 13/41 (31.7%) |
| Event | Placebo | SAGE-547 60 μg/kg/h | SAGE-547 90 μg/kg/h |
|---|---|---|---|
| Intentional overdoseInjury, poisoning and procedural complications | 0/43 | 1/38 | 0/41 |
| Suicidal ideationPsychiatric disorders | 0/43 | 1/38 | 0/41 |
| Event | Placebo | SAGE-547 60 μg/kg/h | SAGE-547 90 μg/kg/h |
|---|---|---|---|
| HeadacheNervous system disorders | 7/43 | 7/38 | 6/41 |
| SomnolenceNervous system disorders | 3/43 | 7/38 | 2/41 |
| DizzinessNervous system disorders | 1/43 | 6/38 | 6/41 |
| Dry mouthGastrointestinal disorders | 0/43 | 4/38 | 0/41 |
| Infusion site painGeneral disorders | 1/43 | 1/38 | 4/41 |
| NauseaGastrointestinal disorders | 3/43 | 1/38 | 0/41 |
| Loss of consciousnessNervous system disorders | 0/43 | 2/38 | 1/41 |
| FlushingVascular disorders | 0/43 | 2/38 | 0/41 |
All randomized participants who started study drug infusion, had a valid baseline HAM-D assessment and at least one post-baseline HAM-D assessment.
| Age, Continuous(years) | Placebo | SAGE-547 60 μg/kg/h | SAGE-547 90 μg/kg/h | Total |
|---|---|---|---|---|
| Mean | 27.2 ± 6.13 | 27.7 ± 6.46 | 27.5 ± 6.05 | 27.4 ± 6.16 |
| Sex: Female, Male(Participants) | Placebo | SAGE-547 60 μg/kg/h | SAGE-547 90 μg/kg/h | Total |
|---|---|---|---|---|
| Female | 43 | 38 | 41 | 122 |
| Male | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | SAGE-547 60 μg/kg/h | SAGE-547 90 μg/kg/h | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 0 | 0 | 1 | 1 |
| Black or African American | 15 | 12 | 8 | 35 |
| Native Hawaiian & Other Pacific Islander | 0 | 0 | 1 | 1 |
| White | 27 | 25 | 29 | 81 |
| Other | 0 | 1 | 2 | 3 |
| Race/Ethnicity, Customized(Participants) | Placebo | SAGE-547 60 μg/kg/h | SAGE-547 90 μg/kg/h | Total |
|---|---|---|---|---|
| Hispanic or Latina | 7 | 3 | 7 | 17 |
| Not Hispanic or Latina | 36 | 35 | 34 | 105 |
| Hamilton Rating Scale for Depression (HAM-D) Total Score(score on a scale) | Placebo | SAGE-547 60 μg/kg/h | SAGE-547 90 μg/kg/h | Total |
|---|---|---|---|---|
| Mean | 28.6 ± 2.54 | 29.0 ± 2.70 | 28.4 ± 2.47 | 28.7 ± 2.55 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.
Ran from Aug 2016 to primary completion in Sep 2017, 13 months.
Results were first posted in Jun 2019, 1 year 8 months after primary completion. A results delay was requested in Sep 2018.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexanolone
Supernus Pharmaceuticals, Inc. →